Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder

NCT03000530 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03000530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03000530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2016
Completion date
November 8, 2017
Enrollment
102 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

major depression